An artificial intelligence system that operates like a collaborative team of medical experts could accelerate clinical trial ...
An artificial intelligence system that operates like a collaborative team of medical experts could accelerate clinical trial design, one of the most difficult steps in drug development, according to a ...
Older patients represent the fastest growing patient group in clinical care. They are a heterogeneous group, for whom evidence for making treatment decisions is often scarce. Important domains for ...
In today's ACT Brief, we examine quantified reductions in trial visits through selective safety data collection, why protocol ...
The rarity of sarcoma complicates clinical trial design and biomarker-driven treatment, explains Alexander Spira, MD, PhD, ...
Clinical trials are notoriously expensive, time consuming, and risky. Failure comes at a very high cost (millions of dollars and months of development time wasted), yet studies show that the rate of ...
Bayer, a global life sciences company, has announced a new strategic alliance focused on clinical trials collaboration with ...
Despite being a cornerstone of cancer treatment advancement, clinical trials remain inaccessible for many patients because of structural, socioeconomic, and systemic barriers. In this ...
Protocol design does not struggle in the protocol. It struggles in the transition to trial, when assumptions embedded in the ...
Clinical trial design decisions impact costs, access, and evidence gaps, with breast cancer as the most studied disease globally. The US leads in trial activity, with China showing rapid growth, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results